Acute Hemodynamic Response to Carvedilol in Children With Clinically Significant Portal Hypertension.
Portal Hypertension
About this trial
This is an interventional treatment trial for Portal Hypertension
Eligibility Criteria
Inclusion Criteria: All children 2-18 years of age with CLD defined as presence of either of the following histological evidence of advanced fibrosis more than F2 on METAVIR staging or radiological imaging suggestive (heterogeneous hepatic echotexture, irregular nodular liver and/or caudate hypertrophy). . Splenomegaly and/or platelets </= 100 (X10^3/mm3) Coming for upper gastrointestinal endoscopy for variceal screening Informed consent for HVPG and UGIE Exclusion Criteria: Uncorrected heart defects (except small ASD) Cardiac conduction defects - arrythmias or heart block Interrupted inferior vena cava Situs inversus Patients who received beta-blockers in last 7 days Patients who received Octreotide infusion or bolus in last 7 days Variceal bleed in last 48 hours Shock or active sepsis Grade 2 /grade 3 ascites Severe hepatic impairment with MELD or PELD score >14 Acute kidney injury (any grade) Hepatic encephalopathy (any grade) Known contraindications to propranolol in children: Hyper-reactive airway disease Hypertrophic cardiomyopathy Acute congestive heart failure
Sites / Locations
- Institute of Liver & Biliary Sciences
Arms of the Study
Arm 1
Experimental
Carvedilol for 1.5 hrs
Carvedilol 0.2 mg/kg for 1.52 hrs